ERBB2 and breast cancer: Elevated PI3K–AKT activity may be mediated by loss-of-function mutations in PTEN (in up to 5% of HER2+ breast cancers) or activating mutations in the PIK3CA gene (seen in approximately 20% of HER2+ cases).